Kailera Therapeutics, Inc. Form 8-K — Nov 4, 2026

Form 8-KItems 2.02, 9.01Filed Nov 4, 2026, 4:08 PM ET0001193125-26-447232Original filing

Kailera Therapeutics (Nasdaq: KLRA) reported Q3 2026 results on November 4, 2026, with a net loss of $95.7 million versus $39.6 million a year ago, driven by R&D spend that tripled to $84.7 million as its obesity pipeline scaled up. The company held $1,037.6 million in cash and marketable securities at quarter end, which management says funds operations into mid-2028 through multiple clinical milestones.

Key figures

Cash runway: into mid-2028
Total assets: 1082178000
Ga expense q3 2025: 13115000
Ga expense q3 2026: 21669000
Rd expense q3 2025: 26994000
Rd expense q3 2026: 84667000
Phase3 participants kainetic: 5000
Phase2b high dose participants: 260
Safiglipron phase2 participants: 300

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.